Tocilizumab and COVID-19: Timing of administration assessment

被引：3

作者：

Richier, Q. ^{[1
]}

Jachiet, V ^{[2
]}

Bonnemains, V ^{[2
]}

Placais, L. ^{[3
]}

Abisror, N. ^{[2
]}

Garnier, M. ^{[4
]}

Pacanowski, J. ^{[1
]}

Dhote, R. ^{[5
]}

Hinchschberger, O. ^{[6
]}

Michel, M. ^{[7
]}

Bienvenu, B. ^{[8
]}

Comarmond, C. ^{[9
]}

Lacombe, K. ^{[1
]}

Mekinian, A. ^{[2
]}

机构：

[1] Sorbonne Univ, Hop St Antoine, AP HP, Serv Malad Infect,Inserm IPLESP, F-75012 Paris, France

[2] Sorbonne Univ, Hop St Antoine, AP HP, Serv Med Interne & Inflammat Immunopathol Biother, F-75012 Paris, France

[3] Hop Bicetre, AP HP, Serv Med Interne & Immunol Clin, Paris, France

[4] Sorbonne Univ, Hop St Antoine, AP HP,GRC 29, Serv Anesthesie Reanimat & Med Peri Operatoire, Paris, France

[5] Hop Avicenne, AP HP, Serv Med Interne, Paris, France

[6] Hop Emile Muller, Serv Med Interne, Mulhouse, France

[7] Hop Henri Mondor, AP HP, Serv Med Interne, Paris, France

[8] Hop St Joseph, Serv Med Interne, Marseille, France

[9] Hop La Pitie Salpetriere, AP HP, Serv Med Interne & Immunol Clin, Paris, France

来源：

INFECTIOUS DISEASES NOW | 2022年 / 52卷 / 01期

关键词：

COVID-19; Oxygen level; SARS-CoV-2; Timing of administration; Tocilizumab;

D O I：

10.1016/j.idnow.2021.06.304

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

Recent evidence showed greater efficacy of tocilizumab (TCZ) in the subgroups of COVID-19 patients who presented with symptoms for less than 7 days and in those only receiving oxygen. We retrospectively analyzed a compassionate use cohort to determine the best timing for TCZ injection. We showed no association between the timing of injection after symptom onset and the efficacy of TCZ on mortality. We then investigated whether the oxygen level at the time of TCZ injection impacted the mortality rate. Our study finally suggested that TCZ could be less effective when oxygen requirement is > 11 L/min and we hypothesized that earlier administration could be associated with better outcome. However, randomized clinical trials are required to confirm this hypothesis.

引用

页码：31 / 34

页数：4

共 8 条

[1] Tocilizumab among patients with COVID-19 in the intensive care unit: a multicentre observational study
Biran, Noa
Ip, Andrew
Ahn, Jaeil
Go, Ronaldo C.
Wang, Shuqi
Mathura, Shivam
Sinclaire, Brittany A.
Bednarz, Urszula
Marafelias, Michael
Hansen, Eric
Siegel, David S.
Goy, Andre H.
Pecora, Andrew L.
Sawczuk, Ihor S.
Koniaris, Lauren S.
Simwenyi, Micky
Varga, Daniel W.
Tank, Lisa K.
Stein, Aaron A.
Allusson, Valerie
Lin, George S.
Oser, William F.
Tuma, Roman A.
Reichman, Joseph
Brusco, Louis, Jr.
Carpenter, Kim L.
Costanzo, Eric J.
Vivona, Vincent
Goldberg, Stuart L.
[J]. LANCET RHEUMATOLOGY, 2020, 2 (10) : E603 - E612
[2] Association Between Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19
Gupta, Shruti
Wang, Wei
Hayek, Salim S.
Chan, Lili
Mathews, Kusum S.
Melamed, Michal L.
Brenner, Samantha K.
Leonberg-Yoo, Amanda
Schenck, Edward J.
Radbel, Jared
Reiser, Jochen
Bansal, Anip
Srivastava, Anand
Zhou, Yan
Finkel, Diana
Green, Adam
Mallappallil, Mary
Faugno, Anthony J.
Zhang, Jingjing
Velez, Juan Carlos Q.
Shaefi, Shahzad
Parikh, Chirag R.
Charytan, David M.
Athavale, Ambarish M.
Friedman, Allon N.
Redfern, Roberta E.
Short, Samuel A. P.
Correa, Simon
Pokharel, Kapil K.
Admon, Andrew J.
Donnelly, John P.
Gershengorn, Hayley B.
Douin, David J.
Semler, Matthew W.
Hernan, Miguel A.
Leaf, David E.
[J]. JAMA INTERNAL MEDICINE, 2021, 181 (01) : 41 - 51
[3] Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia A Randomized Clinical Trial
Hermine, Olivier
Mariette, Xavier
Tharaux, Pierre-Louis
Resche-Rigon, Matthieu
Porcher, Raphael
Ravaud, Philippe
[J]. JAMA INTERNAL MEDICINE, 2021, 181 (01) : 32 - 40
[4] Horby PW, 2021, LANCET, V397, P1637, DOI 10.1016/S0140-6736(21)00676-0
[5] Huang C, LANCET2020
[6] A minimal common outcome measure set for COVID-19 clinical research
Marshall, J. C.
Murthy, S.
Diaz, J.
Cheng, A.
Denholm, J.
Hodgson, C.
Tong, S.
Webb, S.
Bozza, F.
Adhikari, N.
Foster, N.
Fowler, R.
Turgeon, A.
Feng, X.
Qiu, R.
Shi, L.
Zhang, J.
Kojan, R.
Malvey, D.
Bauer, M.
Brunkhorst, F.
Glueck, T.
Wolf, T.
Gomersall, C.
Kumar, B.
Clarke, M.
Laffey, J.
Martin-Loeches, I
Piva, S.
Shimizu, N.
de Jong, M.
Derde, L.
Netea, M.
van de Veerdonk, F.
McArthur, C.
McBride, S.
McGuinness, S.
Morpeth, S.
Salisu-Kabara, H.
Sinclair, J.
Arabi, Y. M.
Kim, Y.
Oh, M-D
Baillie, K.
Dunning, J.
Fletcher, T.
Gobat, N.
Gordon, A.
Horby, P.
McAuley, D.
[J]. LANCET INFECTIOUS DISEASES, 2020, 20 (08) : E192 - E197
[7] Effects of tocilizumab on mortality in hospitalized patients with COVID-19: a multicentre cohort study
Martinez-Sanz, Javier
Muriel, Alfonso
Ron, Raquel
Herrera, Sabina
Perez-Molina, Jose A.
Moreno, Santiago
Serrano-Villar, Sergio
[J]. CLINICAL MICROBIOLOGY AND INFECTION, 2021, 27 (02) : 238 - 243
[8] Outcomes in patients with severe COVID-19 disease treated with tocilizumab: a case-controlled study
Rojas-Marte, G.
Khalid, M.
Mukhtar, O.
Hashmi, A. T.
Waheed, M. A.
Ehrlich, S.
Aslam, A.
Siddiqui, S.
Agarwal, C.
Malyshev, Y.
Henriquez-Felipe, C.
Sharma, D.
Sharma, S.
Chukwuka, N.
Rodriguez, D. C.
Alliu, S.
Le, J.
Shani, J.
[J]. QJM-AN INTERNATIONAL JOURNAL OF MEDICINE, 2020, 113 (08) : 546 - 550

← 1 →